Abstract
Ovarian carcinomas represent a major form of gynaecological malignancies, whose treatment consists mainly of surgery and chemotherapy. Besides the difficulty of prognosis, therapy of ovarian carcinomas has reached scarce improvement, as a consequence of lack of efficacy and development of drug-resistance. The need of different biochemical and functional parameters has grown, in order to obtain a larger view on processes of biological and clinical significance. In this paper we report novel metabolic features detected in a series of different human ovary carcinoma lines, by 1H NMR spectroscopy of intact cells and their extracts. Most importantly, a new ovarian adenocarcinoma line CABA I, showed strong signals in the spectral region between 3.5 and 4.0 p.p.m., assigned for the first time to the polyol sorbitol (39±11 nmol/106 cells). 13C NMR analyses of these cells incubated with [1-13C]-D-glucose demonstrated labelled-sorbitol formation. The other ovarian carcinoma cell lines (OVCAR-3, IGROV 1, SK-OV-3 and OVCA432), showed, in the same spectral region, intense resonances from other metabolites: glutathione (up to 30 nmol/106 cells) and myo-inositol (up to 50 nmol/106 cells). Biochemical and biological functions are suggested for these compounds in human ovarian carcinoma cells, especially in relation to their possible role in cell detoxification mechanisms during tumour progression.
Similar content being viewed by others
Main
Human epithelial ovarian tumours represent a major type of gynaecologic malignancy. The vast majority of ovarian carcinomas arise as a result of malignant transformation of the ovarian surface epithelium. Because of the invasive nature of these tumours and the current inability to detect the disease at early stages (Stage I or II), a significant number of women are initially diagnosed only after the neoplasia has already spread throughout the peritoneal cavity (Stage III or IV). The triggering event(s) in the generation and development of ovarian cancer are not yet well understood. Propagation of epithelial ovarian cancer occurs essentially as a direct infiltration into the peritoneal cavity, upon exfoliation of cells from the primary tumour and dissemination by the peritoneal fluid, with subsequent implantation, invasion and growth (Williams, 2000). To enable the development of appropriate screening strategies for ovarian cancer, the processes of carcinogenesis and tumour progression need to be understood. Since little is as yet known about the morphological and molecular steps involved in the initiation and progression of epithelial ovarian cancer, new biochemical and physiological information, as well as measurement of functional parameters, are of extreme importance in order to obtain a more detailed clinical picture of these tumours.
By allowing non-invasive monitoring of biochemical pathways in intact cells and tissues and their modulations under particular pathological conditions, NMR spectroscopy offers novel approaches to detect metabolic alterations associated with malignant phenotypes of ovarian cancer cells in vitro, as a basis for a possible in vivo monitoring of clinical lesions. In particular, NMR spectra of intact cells and tissues allow detection and quantification of a number of intracellular metabolites (present at intracellular concentrations >about 0.5 mM) and their fluxes in either ubiquitous or tissue-specific biochemical pathways. Among these, particular attention has been devoted to metabolites involved in phospholipid biosynthesis and catabolism (reviewed in Podo, 1999), in oxidative and non-oxidative glucose consumption and in cell bioenergetics (Gadian, 1995; Magistretti et al, 1999), as well as to the production of neurotransmitters, neuroaminoacids and myo-inositol in brain (Danielsen and Ross, 1999; Ross, 2000) and accumulation of citrate in prostate (Kurhanewicz et al, 1996).
The detection by NMR of substrates and derivatives of these pathways and the measurement of their changes in concentration in tumour with respect to non-tumour cells, not only may allow relevant information on activation/inhibition of metabolic processes as they occur in cells, animal models and clinical lesions, but may also provide new biochemical markers of in vivo tumour progression and response to therapy. Examples of major 1H NMR spectral variations reported in tumours, with respect to normal cells and tissues, are a generally elevated intensity of choline-containing metabolites (‘Cho-peak’, 3.2 p.p.m.), mainly due to increased levels of phosphocholine (PCho) in brain, breast, prostate and other tumours (Negendank et al, 1996; Podo, 1999; Aboagye and Bhujwalla, 1999); loss of N-acetylaspartate, a putative neuroaminoacid, in gliomas (Ross, 2000); increase of myo-inositol in some brain tumours (Barba et al, 2001); and decrease of citrate in prostate carcinoma (Kurhanewicz et al, 1995). Furthermore, several tumour cells and tissue specimens exhibit 1H NMR signals attributed to either membrane or intracellular mobile lipid domains (ML), whose fatty chains are endowed with a high degree of mobility, not compatible with the anisotropic packing in the lamellar phase (Mountford et al, 1993; Callies et al, 1993). The relative intensity of these signals was found to discriminate pre-malignant from invasive cancer in tissue specimens dissected from human uterine cervix and thyroid follicular adenomas from carcinomas (Mountford et al, 1996). However, elevated ML levels are not exclusively associated with the malignant phenotype, since they were also induced by cell activation in lymphocytes and lymphoblasts (Veale et al, 1997) and were detected in some embryo-derived cells (May et al, 1986; Ferretti et al, 1999), as well as in different types of cells undergoing apoptosis (Blankenberg et al, 1997; Di Vito et al, 2001). Finally, a rather intense resonance profile may be observed in the so-called ‘CH’ or ‘sugar’ spectral region (3.5–4.0 p.p.m.) of some tumours (e.g. cervical intraepithelial neoplasias), whose individual contributions, however, have not yet been clearly identified (Mountford et al, 1993; Callies et al, 1993).
So far, only a few NMR studies have been reported on human ovarian pathologies, essentially confined to the analysis of fluids from ovarian cysts. By these analyses, significant differences in a variety of soluble metabolite concentrations (some still unassigned) were found between benign and malignant ovarian cysts (Massuger et al, 1998; Boss et al, 2000). No direct investigations were conducted on human ovarian adenocarcinomas.
This paper reports the results of a 1H NMR study on five human ovarian carcinoma cell lines of different origin. This is to our knowledge the first reported evidence on the presence of a polyol in an ovarian cancer cell line (CABA I). High levels of inositol and glutathione were instead detected in the other cell lines examined in this study. The results suggest the interest of further investigating the biochemical pathways responsible for alternative production and accumulation of these soluble metabolites and their implications in self-detoxification processes in human ovarian cancer cell lines.
Materials and methods
Cell lines
The characteristics and origin of all cell lines used in this study are summarised in Table 1 (where they are listed in order of decreasing in vivo tumorigenicity in animal models). The CABA I cell line was established from the ascitic fluid of a patient with ovarian carcinoma prior to any drug treatment. The cell line exhibits complex cytogenetic and mutation patterns, with the possible deletion of the entire exon 5 of the p53 gene (Dolo et al, 1997). SK-OV-3, OVCA432, IGROV 1 and OVCAR-3 cell lines were kindly provided by Dr S Canevari (Istituto Nazionale Tumori, Milano, Italy). Cells were grown as monolayers in RPMI 1640 (Euroclone, Devon, UK) with 10% foetal calf serum (FCS, Euroclone). For each experiment, monolayer cells were harvested in 0.05% Trypsin and 0.02% EDTA (Euroclone), resuspended in RPMI/FCS (complete medium) and then washed three times in PBS. The cells were counted and their viability (80–90%) and membrane integrity assessed by Trypan blue (Euroclone) dye exclusion, both before and after NMR measurements, (during which there was no significant drop in cell viability). All cell lines were periodically tested for mycoplasma contamination.
NMR spectroscopy
Intact cells were resuspended in 600 μl of PBS in 70% (v/v) D2O (pH=7.3) and transferred into 5 mm NMR tubes. The 1H NMR experiments on intact cells were generally carried out on a Bruker Avance 400 MHz WB (9.4 T) spectrometer, at 25°C. Some spectral quantification was also performed on measurements recorded at 200 MHz, using an analytical Varian Gemini 200 NMR spectrometer. One-dimensional (1D) analyses were carried out using a single-pulse (60°) sequence, preceded by 1.0 s presaturation for water signal suppression (spectral width 10.013 p.p.m.), the total measurement time being 17 min for 320 scans. Two-dimensional (2D) 1H-NMR homonuclear shift correlation (COSY) experiments were performed using gradient pulses for selection; the COSY spectra were acquired with eight transients, 256 time domain points in t1, acquisition time 0.27 s, spectral width of 4006.41 Hz in both dimensions, repetition time of 1 s.
Experiments on ethanolic extracts of cells were carried out applying the same pulse sequence as before, at the equilibrium of magnetisation (90° pulses and 30.0 s interpulse delay time). 13C NMR analyses were performed on intact cells incubated with [1-13C]-D-glucose (Merck Sharp and Dohme, Canada, 99.1% isotopic substitution) as well as on their extracts, utilising a sequence with power-gated decoupling pulses. The ethanolic extracts were also analysed by 2D 1H/13C correlation spectroscopy via heteronuclear zero and double quantum coherence, using the HETCOR-inv4tp sequence (Bax et al, 1983) or the modified inv4gp version, that utilises gradient pulses for selection; the samples were recorded in the proton-detected mode.
All types of 1D and 2D NMR analyses were repeated on standard compounds (sorbitol, glutathione, myo-inositol; Sigma-Aldrich, Milano, Italy) for both verification of signal assignments and peak area quantification.
Quantitative data analysis of spectra of intact cells and their extracts was performed in the frequency domain using the Bruker Win-NMR software package. Free induction decays were zero-filled to 32 k data points and Fourier-transformed, after which base line correction was performed, applying a cubic splines model function through appropriate data points. Quantitation was then obtained either through integration (cell extracts) or deconvolution (intact cells) of resonance peaks.
The concentration values of water-soluble metabolites were calculated by peak integration in the spectra of ethanolic cell extracts. In particular, for the quantification of sorbitol all signals were utilised, with reference to a standard solution of this compound (5 mM); the ‘doublet of doublets’ centred at about 3.0 p.p.m., due to the CH2 group of cysteine was used for quantifying glutathione, while the signals around 3.5 p.p.m. (H1 and H3) were used for myo-inositol.
Ethanolic cell extracts
At the end of NMR experiments, cells were extracted by adding five volumes of ethanolic solution (EtOH:H2O, 70:30 v/v). The samples were sonicated at 20 kHz by a MSE ultrasonic disintegrator Mk2 (exponential probe, 8 μm peak to peak) and centrifuged at 14 000 × g for 30 min. The supernatants were lyophilised two times in a RVT 4104 Savant lyophiliser, and the residue resuspended in 700 μl D2O (Sigma-Aldrich, Milano, Italy) containing 3-trimethylsilylpropionate-2,2,3,3-D4 0.1 mM as internal standard (Merck & Co., Montreal, Canada).
Results
Soluble metabolites
1H NMR spectra of intact CABA I cancer cells are shown in Figures 1A and 2. The strong resonances dominating the so-called ‘CH-region’ between 3.5 and 4.0 p.p.m. (Figure 1A) were attributed to sorbitol. The assignment was based upon analytical comparison of the 1D spectrum of the ethanolic cell extract (Figure 1B) with that of a standard solution of D-sorbitol (Figure 1C) and confirmed by 2D-COSY experiments (Figure 2).
It is reasonable to propose that accumulation of sorbitol in these cells is mainly dependent upon the activity of aldose reductase, an enzyme utilising glucose as substrate, with the simultaneous oxidation of NADPH (Scheme 1). In order to verify this hypothesis, CABA I cells, harvested and collected at 72 h of culture, were incubated in the presence of 20 mM [1-13C]-D-glucose in a 5 mm NMR tube at 25°C, and NMR analyses performed on intact and viable cells at various time intervals, up to 10 h (data not shown). The formation of [1-13C]-sorbitol, concomitant with the decrease of the anomeric glucose carbons (both the α and β isoforms, respectively, at 93.2 and 96.9 p.p.m.) and increase in lactate (3-13C, 21.0 p.p.m.), was confirmed by analysing cell extracts by both 1D 13C NMR (signal at 63.4 p.p.m., Figure 3A) and 2D 13C/1H HETCOR spectra (cross-peaks at 3.84/74.2 p.p.m., 3.67/72.3 p.p.m., 3.84/70.8 p.p.m., 3.86/63.8 p.p.m. and 3.80/63.4 p.p.m., Figure 3B). At the end of incubation, when 94% of glucose had been converted into other metabolites, sorbitol reached a concentration of 0.7 mM, indicating that, under these conditions, at least 3.7% of the substrate had been utilised to produce the polyol.
On the other hand, no appreciable levels of sorbitol were detected in the spectral patterns of the other four ovary carcinoma cell lines under investigation (Figure 4). The spectra of these cells were characterised, in the 3.5–4.0 p.p.m. region, by intense signals due to other metabolites, present at variable concentration levels.
Analysis of aqueous cell extracts (Figure 5) demonstrated that the most relevant peak, observed at 3.79 p.p.m., was due to the glycine residue of glutathione, whose other signals were detected at 2.2, 2.5, 3.0 and 4.5 p.p.m. In particular, the presence of reduced glutathione was indicated by the cross-peak at 3.0/4.5 p.p.m. in the 2D-COSY spectra, as can be seen for example in Figure 5 for SK-OV-3 intact cells. Myo-inositol was detected in the spectra of all these cells, as demonstrated by its characteristic signals centred at 3.52 p.p.m. (due to H1 and H3) and the typical cross-peaks at 3.5 p.p.m./4.00 p.p.m. in the 1D and 2D-COSY experiments of intact cells, respectively (Figures 4 and 6). Likewise, all multiplets of myo-inositol, respectively due to H5 (3.26 p.p.m.), H4 (3.61 p.p.m.) and H2 (4.00 p.p.m.) were clearly resolved in the spectra of cell extracts (Figure 5).
The doublet at 1.33 p.p.m. due to H3 from lactate (Figure 4) showed a large variability between experiments of intact cells with no significant differences between the cell lines (the peak area ratio of the lactate doublet to the lysine signal at 1.7 p.p.m. (H3 and H5) was of 0.31±0.12 in CABA I (five experiments) and 0.89±0.75 in the other four ovarian cell lines (in total nine experiments).
Table 2 reports the concentrations of the most relevant water-soluble metabolites measured by 1H NMR in the analysed ovarian cancer cells. The values were determined by peak integration in the spectra of ethanolic cell extracts. These analyses confirmed high levels of sorbitol only in CABA I cells, while glutathione and myo-inositol (but not sorbitol) were present in the other cell lines. The concentration value of 17.3±4.7 nmol/106 cells, corresponding to 75.2±20.0 nmol/mg protein, measured for glutathione in SK-OV-3, was in good agreement with that previously reported by Hosking et al, 1990, for the same cell line (80.7±18.0 nmol/mg protein).
1H NMR analyses of cell extracts also allowed quantification of the molecular components contributing to the so-called ‘Cho-peak’ (3.2 p.p.m. in the spectra of intact cells), mainly PCho (3.22 p.p.m.) and, to much lower extents, glycerophosphorylcholine (GPC, 3.23 p.p.m.) and free choline (Cho, 3.20 p.p.m.). The concentration of PCho reached a mean value of 24 nmol/106 cells in the most tumorigenic cell line (OVCAR-3) and about 15 nmol/106 cells in CABA I (Table 2).
Mobile lipids
The proton spectra of some intact ovarian cancer cells showed the typical signals arising from ‘mobile lipids’, i.e. lipids comprised in structures endowed of sufficiently high isotropic mobility to be detected by high resolution NMR spectroscopy. In particular, the presence of ML was recognised by the peak at 1.27 p.p.m., due to (CH2)n segments of fatty acyl chains, next to the peak of lactate at 1.33 p.p.m., and by the large composite resonance centred at 0.89 p.p.m., typically comprising contributions from the chains' terminal CH3, superimposed on those of cholesterol methyl groups (at position 18, 19, 21, 26, 27) and of amino acids' methyl groups (Figure 4). The ratio (R) between the 1.27 p.p.m. and the 0.89 p.p.m. peak areas, usually adopted as empirical parameter for relative ML quantification, was 1.5±0.4 in SK-OV-3 cells, in which the presence of ML was confirmed by the typical cross peak at 0.9 p.p.m./1.3 p.p.m. (Figure 6). The other ovarian cancer cell lines exhibited much lower R values (Table 2), while CABA I cells were practically deprived of mobile (CH2)n segments, as also shown by 2D COSY spectra (Figure 2).
Discussion
This study provides evidence on the presence, in five human ovarian carcinoma cell lines, of 1H NMR-detectable amounts of metabolites such as sorbitol, reduced glutathione and myo-inositol. These compounds are typically implicated in cellular detoxification pathways, although they may act as osmolites. Sorbitol may furthermore compete for intracellular stores of myo-inositol, inducing depletion of this metabolite (Kuruvilla and Eichberg, 1998). As a consequence, different levels of myo-inositol may also influence the biosynthesis and turnover of phospholipids.
CABA I cells were characterised by high levels of sorbitol (39±11 nmol/106 cells). Accumulation of this compound has been reported to occur in some non-tumour tissues, such as the crystalline lens and nerves of patients affected by diabetes (Kuruvilla and Eichberg, 1998), as a complication of this pathology (Kinoshita, 1990). A high level of sorbitol may even induce fracture of the lens. Regarding tumour cells, an elevated concentration of sorbitol has been found to induce resistance to cis-platinum in human non-small-cell lung cancer cell lines, by modulating the activity of Na+, K+ ATPase (Bando et al, 1997).
Sorbitol is mainly produced in the cells from glucose by the aldose reductase pathway (Scheme 1). The general role of such enzyme, expressed in some tissues and organs, is not yet well clarified. Regarding tumours, an aldose reductase activity has been identified in rat hepatoma, in which it was suggested to play an important role in cell detoxification from harmful metabolites, such as aldehydes, generated by intracellular metabolism. Moreover, this enzyme has been reported to display a high sequence homology with a novel human aldose reductase, overexpressed in human liver cancer (Cao et al, 1998).
Recent studies also reported that aldose reductase can convert daunorubicin into its reduced form, daunorubicinol, thus decreasing the pharmacological activity of this anti-tumour drug (Ax et al, 2000).
This body of evidence suggests that accumulation of sorbitol in CABA I cells might be an index of increased metabolic flux through the aldose reductase pathway, by which these fast growing cancer cells would likely enhance their capability of self-detoxification, through reduction of aldehydes or other similar (either endogenous or exogenous) compounds, including anti-cancer drugs.
Additionally, an indirect detoxification process could be triggered in these cells, by activation of the pentose phosphate shunt, in which NADP produced from NADPH in the aldose reductase pathway is effectively utilised. Besides, the pentose phosphate shunt is directly involved in nucleic acid ribose synthesis and in proliferation of pancreatic and lung epithelial carcinoma cells; the control of this shunt may be critical in cancer treatment, as recently reported by Boros et al, 2000. Furthermore, sorbitol could as well be synthesised from fructose via the activated pentose phosphate pathway from glucose and ribose and sorbitol dehydrogenase (Jans et al, 1989).
Under our experimental conditions, we could directly demonstrate the formation of 13C-labelled sorbitol from [1-13C]glucose in CABA I cells, thus confirming that this polyol can effectively be synthetised from this common substrate, through the described fluxes.
Quantification of the individual contributions provided by these detoxification pathways to the elevated concentration of sorbitol, and their alterations under different conditions of cell exposure to either cytotoxic drugs and/or to supplementation with specific substrates (such as folate, reported to interfere with the activity of sorbitol dehydrogenase (Vandenberghe et al, 1995)) would enhance our understanding of the significance of sorbitol accumulation in relation to the responsiveness of CABA I cells to combined anticancer therapies. This perspective appears particularly interesting in view of the recent demonstration that CABA I cells possess mutated α-folate receptors, associated with molecules regulating cell proliferation, but with impaired affinity for folates (Mangiarotti et al, 2001).
The other four carcinoma cell lines exhibited, instead of sorbitol, high levels of glutathione and myo-inositol, metabolites likewise known for being involved in detoxification processes of the cells. In particular, the role of the glutathione system in the development and maintenance of multi-drug resistance has been demonstrated in some tumour cells (Hosking et al, 1990; Ferretti et al, 1993). Regarding myo-inositol, although the complexity of the pathways responsible for the synthesis and turnover of this metabolite so far prevented a clear elucidation of the role of this compound in cerebral tumours and in some cognitive diseases, the view is growing that myo-inositol does not act as a simple osmolyte (Ross, 2000).
The detection in the present work of high levels of myo-inositol and glutathione in ovarian cancer cells (in particular in the most tumorigenic line investigated, i.e. OVCAR-3) stimulates the interest of further investigating their role as cell detoxification agents and as possible indicators of tumour progression of ovarian cancer in vivo.
Besides identifying compounds, which mainly affect the CH region, 1H NMR allowed likewise the detection in intact ovarian cancer cells of a strong ‘Cho’–peak, mostly due to PCho. This metabolite reached substantial levels in some of the investigated cells, similar to and even higher than those detected in some cell lines derived from other human epithelial tumours, such as breast (Aboagye and Bhujwalla, 1999) or prostate (Ackerstaff et al, 2001) carcinomas.
Regarding mobile lipid domains, there was quite a large variability in the detection of their typical signals in 1H NMR spectra of the different intact carcinoma cell lines analysed in this study, with no association with their respective origin and/or in vivo tumorigenicity. Very similar R values were found in three cell lines IGROV 1, OVCAR-3 and OVCA432 (R∼0.5) which, differently from SK-OV-3 (R∼1.5) are characterised by high levels of α-folate receptors and by low or absent levels of caveolin-1 expression (Bagnoli et al, 2000). The existence of a possible relationship between the detection of NMR-visible ML domains and caveolin-1 expression deserves further investigation.
In conclusion, in this study we report the possibility to detect and quantify by 1H NMR previously unidentified components of intact ovarian carcinoma cell lines. This evidence may open novel ways to the analysis and interpretation of 1H NMR spectra of ovarian tumour tissues in vivo and ex vivo.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59: 80–84
Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM (2001) Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostate epithelial cells. Cancer Res 61: 3599–3603
Ax W, Soldan AW, Kock L, Maser E (2000) Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59: 293–300
Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S (2000) Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 19: 4754–4763
Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, Iwasa K, Ueda A, Tomikawa S, Matsuda T (1997) Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines. Anticancer Res 17: 3345–3348
Barba I, Moreno A, Martinez-Perez I, Tate AR, Cabañas ME, Baquero M, Capdevila A, Arus C (2001) Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas. J Neurosurg 94: 55–60
Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331–1337
Bax A, Griffey RH, Hawkins BL (1983) Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. J Magn Reson 55: 301–315
Benard J, Da Silva J, De Blois M-C, Boyer P, Duvillard P, Chiric E, Riou G (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in a tissue culture and in nude mice. Cancer Res 45: 4970–4979
Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF (1997) Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 89: 3778–3786
Boros LG, Torday JS, Lim S, Bassilian S, Cascante M, Lee WN (2000) Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Res 60: 1183–1185
Boss EA, Moolenaar SH, Massuger LFAG, Boonstra H, Engelke UFH, de Jong JGN, Wevers RA (2000) High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed 13: 297–305
Callies R, Sri-Pathmanathan RM, Ferguson DYP, Brindle KM (1993) The appearance of neutral lipid signals in the 1H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmic lipid droplets. Magn Res Med 29: 546–550
Cao D, Fan ST, Chung SSM (1998) Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 273: 11429–11435
Danielsen ER, Ross BD (1999) Magnetic Resonance Spectroscopy in Neurological Diagnosis. New York: Marcel Dekker
Di Vito M, Lenti L, Knijn A, Iorio E, D'Agostino F, Molinari A, Calcabrini A, Stringaro A, Meschini S, Arancia G, Bozzi A, Strom R, Podo F (2001) 1H NMR-visible lipid domains correlate with cytoplasmic lipid bodies in apoptotic T-lymphoblastoid cells. Biochim Biophys Acta 1530: 47–66
Dolo V, Ginestra A, Violini S, Miotti S, Festuccia C, Miceli D, Migliavacca M, Rinaudo C, Romano FM, Brisdelli F, Canevari S, Pavan A (1997) Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Oncol Res 9: 129–138
Ferretti A, Chen LL, Di Vito M, Barca S, Tombesi M, Cianfriglia M, Bozzi A, Strom R, Podo F (1993) Pentose phosphate pathway alterations in multi-drug resistant leukemic T-cells: 31P NMR and enzymatic studies. Anticancer Res 13: 867–872
Ferretti A, Knijn A, Iorio E, Pulciani S, Giambenedetti M, Molinari A, Meschini S, Stringaro A, Calcabrini A, Freitas I, Strom R, Podo F (1999) Biophysical and structural characterization of 1H NMR-detectable mobile lipid domains in NIH-3T3 fibroblasts. Biochim Biophys Acta 1438: 329–348
Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221–226
Gadian DG (1995) NMR and its Applications to Living Systems. Oxford: University Press
Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Gree WR, Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379–5389
Hosking LK, Whelan RDH, Shellard SA, Bedford P, Hill BT (1990) An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem Pharmacol 40: 1833–1842
Jans AWH, Grunewald RW, Kinne RKH (1989) Pathways for the synthesis of sorbitol from 13C-labeled hexoses, pentose and glycerol in renal papillary tissue. Magn Reson Med 9: 419–422
Kinoshita JH (1990) A thirty year journey in the polyol pathway. Exp Eye Res 50: 567–573
Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P (1995) Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 45: 459–466
Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7 cm3) spatial resolution. Radiology 198: 795–805
Kuruvilla R, Eichberg J (1998) Depletion of phospholipid arachidonyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by aldose reductase inhibitor. J Neurochem 71: 775–783
Magistretti PJ, Pelelrin L, Rothman DL, Shulman RG (1999) Energy on demand. Science 283: 496–497
Mangiarotti F, Miotti S, Galmozzi E, Mazzi M, Sforzini S, Canevari S, Tomassetti A (2001) Functional effect of point mutations in the α-folate receptor gene of CABA I ovarian carcinoma cells. J Cell Biochem 81: 488–498
Massuger LFAG, van Vierzen PBJ, Engelke U, Heerschap A, Wevers R (1998) 1H-Magnetic Resonance Spectroscopy. A new technique to discriminate benign from malignant ovarian tumors. Cancer 82: 1726–1730
May GL, Wright LC, Holmes KT, Williams PG, Smith ICP, Wright PE, Fox RM, Mountford CE (1986) Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane tiglyceride. J Biol Chem 261: 3048–4053
Mountford CE, Lena CL, Mackinnon WB, Russell P (1993) The use of proton MR in cancer pathology. In:: Annual Reports on NMR Spectroscopy Webbs GA (ed),27: pp 173–215, New York: Academic Press
Mountford CE, MacKinnon VB, Russell P, Rutter A, Delikatny EJ (1996) Human cancers detected by proton MRS and chemical shift imaging ex vivo. Anticancer Res 16: 1521–1532
Negendank W, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BC, Mengeot MM, Moser E, Padavich-Shaller KA, Sanders JA, Spraggins TA, Stillman AE, Terwey B, Vogl TJ, Wiclow K, Zimmerman RA (1996) Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 84: 449–458
Podo F (1999) Tumour phospholipid metabolism. NMR Biomed 12: 413–439
Ross BD (2000) Real or imaginary? Human metabolism through nuclear magnetism. IUBMB Life 50: 177–187
Vandenberghe Y, Masson M, Palate B, Roba J (1995) Effect of folate supplementation on clinical chemistry and hematologic changes related to bidisomide administration in the rat. Drug Chem Toxicol 18: 235–270
Veale MF, Roberts NJ, King GF, King NJC (1997) The generation of 1H-NMR-detectable mobile lipid in stimulated lymphocytes: relationship to cellular activation, the cell cycle, and phosphatidylcholine-specific phospholipase C. Biochem Biophys Res Commun 239: 868–874
Williams ARW (2000) Ovarian Cancer: Methods and Protocols Bartlett JMS (ed), Totowa: Humana Press Inc
Acknowledgements
This work was supported by grants from the Italian Ministry of University and Scientific and Technological Research (MURST) and from Ministero del Lavoro e Previdenza Sociale n. 792. We thank Mr Massimo Giannini for excellent technical assistance and maintenance of the NMR equipment.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ferretti, A., D'Ascenzo, S., Knijn, A. et al. Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA I: a1H NMR study. Br J Cancer 86, 1180–1187 (2002). https://doi.org/10.1038/sj.bjc.6600189
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600189
Keywords
This article is cited by
-
Investigation of altered urinary metabolomic profiles of invasive ductal carcinoma of breast using targeted and untargeted approaches
Metabolomics (2018)
-
NMR Based Metabonomics Study of DAG Treatment in a C2C12 Mouse Skeletal Muscle Cell Line Myotube Model of Burn-Injury
International Journal of Peptide Research and Therapeutics (2011)
-
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug
Investigational New Drugs (2007)
-
High-resolution magic angle spinning 1H NMR spectroscopy of metabolic changes in rabbit lens after treatment with dexamethasone combined with UVB exposure
Graefe's Archive for Clinical and Experimental Ophthalmology (2004)